These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8724536)

  • 1. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.
    Robak T; Błasińska-Morawiec M; Krykowski E; Hansz J; Komarnicki M; Kazimierczak M; Konopka L; Maj S; Hellmann A; Zaucha JM; Urasiński L; Zdziarska B; Kotlarek-Haus S; Usnarska-Zubkiewicz L; Kuratowska Z; Dwilewicz-Trojaczek J; Hołowiecki J; Krawczyk-Kulis M; Grieb P
    Leuk Lymphoma; 1996 Jun; 22(1-2):107-11. PubMed ID: 8724536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with hairy cell leukemia with 2-chloro-2'-deoxyadenosine (2-CdA).
    Robak T; Krykowski E; Błasińska-Morawiec M; Urbańska-Ryś H
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):25-9. PubMed ID: 7503629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
    Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
    Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
    Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
    Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
    Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
    Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
    Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
    Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
    Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.
    Palomera L; Domingo JM; Sola C; Azaceta G; Calvo MT; Gutierrez M
    Haematologica; 2002 Jan; 87(1):107-8. PubMed ID: 11801472
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.
    Lauria F; Rondelli D; Zinzani PL; Bocchia M; Marotta G; Salvucci M; Raspadori D; Ventura MA; Birtolo S; Forconi F; Tura S
    Leukemia; 1997 May; 11(5):629-32. PubMed ID: 9180283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients.
    Marotta G; Frassoldati A; Zinzani P; Annino L; Brugiatelli M; Ambrosetti A; Lenoci M; Federico M; Foa R; Lauria F;
    Eur J Haematol; 2006 Aug; 77(2):109-13. PubMed ID: 16856905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia.
    Damasio EE; Resegotti L; Masoudi B; Bruni R; Cerri R; Isaza A; Clavio M; Risso M; Rossi E; Spriano M; Truini M
    Recenti Prog Med; 1998 Feb; 89(2):68-73. PubMed ID: 9558908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retreatment with 2-CdA of progressed HCL patients.
    Lauria F; Benfenati D; Raspadori D; Rondelli D; Ventura MA; Pileri S; Sabattini E; Poggi S; Benni M; Tura S
    Leuk Lymphoma; 1994; 14 Suppl 1():143-5. PubMed ID: 7820047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyserythropoietic changes and sideroblastic anemia in patients with hairy cell leukemia before and after therapy with 2-chlorodeoxyadenosine.
    Zák P; Chrobák L; Podzimek K; Plísková L; Dedic K
    Neoplasma; 1998; 45(4):261-5. PubMed ID: 9890671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful ambulatory treatment of patients with hairy-cell leukemia using one cycle of the purine analog cladribine. 'Hemato-oncologic volwassen Nederland' (HOVON) Study Group].
    Raemaekers JM; van 't Veer MB; Bogman MJ
    Ned Tijdschr Geneeskd; 1996 Aug; 140(31):1600-4. PubMed ID: 8768814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2-chlorodeoxyadenosine therapy.
    Gillis S; Amir G; Bennett M; Polliack A
    Eur J Haematol; 2001 Jan; 66(1):7-10. PubMed ID: 11168501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.
    Öngören Ş; Eşkazan AE; Berk S; Elverdi T; Salihoğlu A; Ar MC; Başlar Z; Aydın Y; Tüzüner N; Soysal T
    Turk J Haematol; 2017 Dec; 34(4):291-299. PubMed ID: 29199176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hairy cell leukemia patients with 2-chloro-2'-deoxyadenosine (2-CdA).
    Komarnicki M; Kaźmierczak M; Hansz J
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):31-2. PubMed ID: 7503630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.
    Juliusson G; Heldal D; Hippe E; Hedenus M; Malm C; Wallman K; Stolt CM; Evensen SA; Albertioni F; Tjønnfjord G
    J Clin Oncol; 1995 Apr; 13(4):989-95. PubMed ID: 7707128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.